Cardiotoxicity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Cardiotoxicity Market Outlook

Thelansis’s “Cardiotoxicity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiotoxicity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cardiotoxicity Overview

Cardiotoxicity is a comprehensive term that covers a wide range of effects on the heart, including detectable structural alterations without symptoms, leading to arrhythmias, increased cardiac biomarkers due to stress and heart injury, and both systolic and diastolic dysfunction in the left ventricle, even without signs of heart failure. Cardiotoxicity is a well-recognized complication of fluoropyrimidines, namely 5-fluorouracil and its oral prodrug capecitabine. The risk of this adverse effect is heightened in patients undergoing thoracic radiation therapy simultaneously with multiagent chemotherapy, particularly if there's preexisting cardiac disease. The incidence of cardiotoxicity can be as high as 18% among individuals exposed to fluoropyrimidines. Cardiac toxicity can present in two forms, reversible or irreversible. Reversibility denotes the ability to regain cellular or organ function. However, certain myocardial changes, such as loss of myocardial cells through necrosis or apoptosis, loss of myofibrils, and deterioration of mitochondria, are generally considered irreversible in cellular or tissue damage. As per the cardiac review committee's assessment, drug-induced cardiotoxicity, specifically cardiomyopathy, involves one or more of the following criteria: (i) a reduction in left ventricular ejection fraction (LVEF), either throughout the ventricle or more prominently in the septum; (ii) indications and symptoms of heart failure, such as rapid heartbeat and S3 gallop; (iii) a decrease in LVEF that ranges from equal to or greater than 10% but less than 55%, without accompanying signs and symptoms of heart failure, or an LVEF decrease from equal to or less than 5% but less than 55%, combined with signs and symptoms of heart failure.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: